Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Jin Hee Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5036-3326; OpenAlex author ID A5100444266. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers

Papers 18

  1. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16437-9↗
  2. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16618-6↗
  3. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Co-author DOI 10.1007/s00261-024-04299-4↗
  4. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and 1… Co-author DOI 10.3348/kjr.2023.1235↗
  5. Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct CT and MRI Characteristics. Co-author DOI 10.3348/kjr.2023.0521↗
  6. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Co-author DOI 10.1002/jhbp.1192↗
  7. MRI features for differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.dld.2021.11.013↗
  8. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.1007/s00330-020-07134-8↗
  9. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Co-author DOI 10.1007/s00330-020-07188-8↗
  10. Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma. Co-author DOI 10.1007/s00330-020-07416-1↗
  11. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis. Co-author DOI 10.1007/s00330-020-07433-0↗
  12. Meta-analysis of MRI for the diagnosis of liver metastasis in patients with pancreatic adenocarcinoma. Co-author DOI 10.1002/jmri.26969↗
  13. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  14. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of … Co-author DOI 10.1148/radiol.2020200281↗
  15. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase. First author DOI 10.1007/s00330-019-06200-0↗
  16. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00330-018-5565-1↗
  17. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria. Co-author DOI 10.1148/radiol.2018180628↗
  18. Diagnostic Strategy for Differentiating Autoimmune Pancreatitis From Pancreatic Cancer: Is an Endoscopic Retrograde Pancreatography Essential? Co-author DOI 10.1097/mpa.0b013e31823a509b↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hyoung Jung Kim · 15 shared papers, 2018–2025 · strength 2.32
  2. Jae Ho Byun · 15 shared papers, 2012–2025 · strength 2.14
  3. Seung Soo Lee · 15 shared papers, 2012–2025 · strength 2.08
  4. Song Cheol Kim · 10 shared papers, 2018–2025 · strength 1.53
  5. Kyu‐pyo Kim · 8 shared papers, 2020–2025 · strength 1.24
  6. Changhoon Yoo · 8 shared papers, 2020–2025 · strength 1.24
  7. Seung‐Mo Hong · 7 shared papers, 2018–2025 · strength 1.18
  8. Jong Keon Jang · 6 shared papers, 2021–2025 · strength 1.05
  9. Dae Wook Hwang · 5 shared papers, 2020–2025 · strength 0.88
  10. Se Jin Choi · 4 shared papers, 2022–2025 · strength 0.79
  11. Dong‐Wan Seo · 4 shared papers, 2021–2025 · strength 0.68
  12. Sang Hyun Choi · 3 shared papers, 2020–2022 · strength 0.48
  13. Seung Baek Hong · 3 shared papers, 2018–2021 · strength 0.35
  14. Jiyeon Ha · 2 shared papers, 2021–2022 · strength 0.35
  15. Dong Wan Seo · 2 shared papers, 2020–2025 · strength 0.31
  16. Dong Wook Kim · 2 shared papers, 2020–2023 · strength 0.29
  17. Woohyung Lee · 2 shared papers, 2020–2024 · strength 0.29
  18. Ki Byung Song · 3 shared papers, 2018–2020 · strength 0.28
  19. Ji Hun Kang · 2 shared papers, 2021 · strength 0.25
  20. Moon-Gyu Lee · 3 shared papers, 2012–2021 · strength 0.23
  21. Baek‐Yeol Ryoo · 2 shared papers, 2020–2021 · strength 0.22
  22. Boryeong Jeong · 1 shared paper, 2024 · strength 0.21
  23. Myung‐Hwan Kim · 3 shared papers, 2012–2020 · strength 0.20
  24. Eun Joo Park · 1 shared paper, 2024 · strength 0.20
  25. Sung Joo Kim · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.